01.0082 :    Hematologic Malignancies, Leukemia, Lymphoma

Purpose:  A research study to determine the effectiveness of giving donor cells treated with an investigational drug, L-leucyl-L-leucine methyl ester (LLME), to improve the recovery of the immune system following stem cell transplant.

Title:  LLME Treated Cellular Immunotherapy Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acceleration of Immune Reconstitution

01.0823 :  Newly diagnosed colorectal carcinoma  Colorectal, Prevention & Control

Purpose:  The purpose of this study is to determine if a new diagnostic test is useful in determining whether colon cancer has spread outside the colon.

Title:  GCC Staging of Lymph Nodes Harvested During Colorectal Cancer Surgery: Evaluating Patients For ‘Time to Recurrence’

01.1028R :    Prostate, Prevention & Control

Purpose:  A research trial testing selenium for prostate cancer prevention.

Title:  Phase III Trial of Selenium for Prostate Cancer Prevention (NIH/NCI)

01.9062 :  Resected Stage I  Prevention & Control, Lung & other Thoracic Malignancies

Purpose:  The purpose of this study is to find out if a high selenium yeast tablet can prevent new lung cancers in people with surgically removed non-small cell lung cancer.

Title:  E5597: Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected State I Non-Small Cell Lung Cancer

02U.282 :    Breast

Purpose:  A research study to evaluate the use of a device that helps coordinate the breathing cycle so that radiation treatment of the breast can be given during breathing in order to minimize radiation of normal structures around the breast.

Title:  A Pilot Study Investigating Active Breathing Coordinator (ABC) to Reduce Radiation Dose to Normal Structures in Breast Cancer Patients

02U.88 :    Hematologic Malignancies

Purpose:  A Research Study to Analyze your White Blood Cells, Bone Marrow Cells or Left Over Tissue from Biopsy After your Bone Marrow Transplant.

Title:  Analysis of Donor Cells Engrafted in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

02U.89 :    Hematologic Malignancies

Purpose:  A Research Study Using your White Blood Cells and/or Bone Marrow Cells for Studying Ways to Improve the Efficacy of the Procedure.

Title:  Analysis of Donor Cells in Allogeneic Hematopoietic Stem Cell Transplantation

03C.286 :    Prostate

Purpose:  To determine which is better treatment a prostate implant alone or with external beam radiation therapy

Title:  RTOG #0232: A Phase III Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate Risk Prostatic Carcinoma.

03U.42 :    Hematologic Malignancies

Title:  A Research Database for Allogeneic and Autologous Hematopoietic Progentior Cell Transplantation

03U.43 :    Hematologic Malignancies

Title:  Protocol for a Research Sample Repository for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation

04F.30 :    Brain & Central Nervous System

Purpose:  Research study to determine the safety of the chemotherapy drug, temozolomide when used with rituximab and methotrexate and the effect these drugs followed by radiation therapy and additional temozolomide will have on your tumor

Title:  RTOG #0227: A Phase I/II Study of Pre-Irradiation Chemotherapy with Methotrexate, Rituximab, and Temozolomide and Post-Irradiation Temozolomide for Primary Central Nervous System Lymphoma

04F.300 :  Stage III Colon Cancer  Colorectal

Purpose:  A research study to find out if adding an investigational drug, C225 to standard chemotherapy (Oxaliplatin, 5-FU, and Leucovorin) increases the effectiveness of this standard treatment in preventing the return of your colon/rectal cancer.

Title:  N0147: A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) After Curative Resection for Patients with Stage III Colon Cancer

04F.389 :    Ovary

Title:  Levels of Distress in Women with Family History of Ovarian Cancer.

04F.413 :    Prevention & Control, Prostate

Purpose:  A research study to determine the effects (good and bad) of supplements, selenium, vitamin E, and selenium plus vitamin E, in preventing or reducing the occurrence of cataract and age-related macular degeneration (AMD) in a large group of men already in SELECT for the prevention of prostate cancer.

Title:  SWOG #0000B: Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE), Ancillary to S0000

04F.445 :    Melanoma

Title:  Immunoembolization of Hepatic Artery with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

04F.445R :    Melanoma

Title:  Immunoembolization of Hepatic Artery with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)

04F.479 :  IV  Brain & Central Nervous System, Lung & other Thoracic Malignancies

Purpose:  A research study to determine if adding chemotherapy drugs to standard radiation therapy will better control your tumor than radiation therapy alone.

Title:  RTOG #0320: A Phase III Trial Comparing Whole Brain Radiation and Stereotactic Radiosurgery Alone Versus With Temozolomide or Erlotinib in Patients with Non-Small Cell Lung Cancer and 1-3 Metastases

04F.550 :    Prevention & Control

Purpose:  A research study to collect female organ tumor tissue and blood from subjects to learn more about their disease.

Title:  GOG #136: Acquisition of Human Gynecologic Specimens and Serum to be used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer

04F.551 :    Endometrial & Uterine Cancers

Purpose:  A research study to collect blood, tissue and urine and information from patients who have endometrial cancer to predict their future outcome about this disease.

Title:  GOG #210: A Molecular Staging Study of Endometrial Cancer

04U.177R :    Hematologic Malignancies

Purpose:  A Research Study to Test the Safety and Effectiveness of VELCADE in the Treatment of Graft-versus Host Disease in Patients Who Do Not Respond to Steroids.

Title:  Phase II Trial of VELCADE (Bortezomib) for Steroid Refractory Acute Graft-Vs-Host Disease

04U.421 :    Prevention & Control

Purpose:  A study to gather information from individuals and families identified at increased risk for a cancer passed down from gereration to generation in a family (Hereditary Cancer)

Title:  Jefferson Hereditary Cancer Registry

05C.255 :  All stages  Brain & Central Nervous System, Head & Neck, Cervix

Purpose:  A research study to determine the safety of an investigational drug VELCADE when combined with radiation therapy and chemotherapy.

Title:  A Phase 1, Open-Label, Dose-Escalation, Safety Study of the Combination of VELCADE and Chemoradiation for the Treatment of Patients with Cancer

05C.540 :  Stage III or IV  Uveal Melanoma

Title:  M-Vax: A feasibility and bio-equivalence study using a DNP-modified autologous melanoma tumor cell vaccine as therapy in pts. with stage III or IV Protocol A/100/0401

05F.129 :    Breast

Purpose:  This study is trying to determine if giving partial breast irradiation is as effective as whole breast irradiation for early stage breast cancer.

Title:  RTOG #0413: A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, II Breast Cancer (NSABP B-39)

05F.197 :    Prevention & Control

Title:  Nonlinear models of mRNA expression in cancer by RT-PCR

05F.294 :    Psychosocial Interventions

Purpose:  Comparison of Cancer Support Programs.

Title:  MBAT: A Novel Psychosocial Cancer Intervention

05F.335 :    Prevention & Control

Purpose:  A study to assess the biobehavioral risk factors for oral premalignant lesions.

Title:  Bio-Behavioral Pathways in Oral Lesions

05F.513 :  Stage II: T3N0 or T4N0 Stage III: T1-2,N1; T3-4,N1; AnyT,N2  Colorectal

Purpose:  A Research Study to Compare the Results of Radiation Treatment Combined with Two Different Chemotherapy Drugs in Treating Rectal Cancer

Title:  NSABP #R-04: A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine With or Without Oxaliplatin With Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) With or Without Oxaliplatin in the Treatment of Patients With Operable Carcinoma of the Rectum

05U.443R :  stage IV  Brain & Central Nervous System

Purpose:  A research study to determine if using intensity modulated radiation therapy (IMRT) for brain metastases is safe and better control this tumor than standard whole brain radiation therapy

Title:  Phase I Dose Escalation Trial in Patients with Brain Metastases Using IMRT

05U.506 :    Hepatocellular

Title:  The Liver Biobank – Tissue/Clinical Database

06C.203 :    Head & Neck

Purpose:  A data base to help physicians better understand how to treat head and neck cancer

Title:  Prospective, Longitudinal, Multi-Center, Descriptive Registry of Patients Receiving Therapy Other than Surgical Resection Alone for Newly Diagnosed Head and Neck Carcinoma.

06C.342 :    Prostate

Purpose:  A study to test the difference between HIFU and Cryotherapy.

Title:  Ablatherm(R) Integrated Imaging High Intensity Focused Ultrasound (HIFU) Indicated for Treatment of Low Risk, Localized Prostate Cancer

06C.46 :    Head & Neck

Title:  A Phase I Study of Combination Chemo-radiotherapy with Biologic Therapy for Advanced Head and Neck Cancer [Bevacizumab IND #12,907] Original: 1/26/06; Revised 3/24/06)

06C.549 :    Brain & Central Nervous System, Head & Neck, Pelvic Malignancies, Lung & other Thoracic Malignancies

Purpose:  A research study to determine the safety of an investigational drug Sunitinib when combined with radiation therapy.

Title:  A PHASE IB, OPEN-LABEL, SAFETY STUDY OF THE COMBINATION OF SUNITINIB AND RADIATION FOR THE TREATMENT OF PATIENTS WITH CANCER

06F.145 :    Prostate

Purpose:  A research study to see if treatment with a drug that can reduce blood flow in the prostate will help to improve detection of prostate cancer in patients scheduled for prostate biopsy, aided by ultrasound imaging with a contrast (dye) agent.

Title:  US Prostate Cancer Detection with Dutasteride Pretreatment (NIH GRANT No.: 1R01CA118003-01A1)

06F.194 :    Miscellaneous

Purpose:  Studies that have been placed on the ECOG Long-Term Follow-Up Protocol E1292 E1484 E3189 E3489 PZ489 E2188 E2197 E3193 E4181 E4188 E4494 E5188 E9887 S9304 E5489 C9344

Title:  Long Term Follow-up Protocol for Eastern Cooperative Oncology Group

06F.200 :    Prostate

Purpose:  To determine if a higher daily dose of radiation therapy is better than the standard dose

Title:  RTOG #0415: A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients with Favorable-Risk Prostate Cancer.

06F.302 :    Renal

Purpose:  A research study to compare the good and bad side effects and effectiveness of the investigational agents, Sunitinib and Sorafenib, in patients with renal cancer.

Title:  E2805 (CIRB): ASSURE Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma

06F.304 :    Gastric

Title:  Gene Environmental Risk Assessment and CRC Screening.

06F.312 :    Cervix

Purpose:  A research study to determine if adding an investigational agent, Tirapazamine, to standard chemotherapy and radiation, will help patients with cervical cancer.

Title:  GOG #219: A Phase III, Randomized Trial of Weekly Cisplatin and Radiation versus Cisplatin and Tirapazamine and Radiation in Stage IB2, IIA, IIB, IIIB and IVA Cervical Carcinoma Limited to the Pelvis

06F.447 :    Breast

Purpose:  A research study to determine whether patients who have a tumor with a higher score (11-25) on a certain diagnostic test [called Oncotype DX Recurrence Score] benefit from chemotherapy, and to confirm that patients with a lower score on this same diagnostic test (less than 10) have a very low risk of their disease reoccurring with hormonal therapy alone.

Title:  PACCT-1: (CIRB) Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial

06F.49 :    Prostate

Purpose:  To determine if adding chemotherapy to the standard treatment, hormones and radiation therapy, will better control localized high risk prostate cancer

Title:  RTOG #0521: A Phase III Protocol of Androgen Suppresion (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate Cancer.

06F.526 :    Colorectal

Title:  Tailored Navigation in CRC Screening

06U.20 :    Hematologic Malignancies

Title:  A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies from HLA Partially-Matched Related Donors

06U.296 :    Miscellaneous

Title:  Screening for Distress in Cancer Patients on In-Patient Units.

06U.328 :    Stem Cell Transplantation

Purpose:  Bone Marrow Transplant for Patients Without Completely Matched Donors Using a Dose-Reduced Treatment Regimen That is Given in 2 Steps.

Title:  A Two Step Approach To Reduced Intensity Allogeneic Hematopietic Stem Cell Transplantation for Hematologic Malignancies from HLA Partially-Matched Donors.

06U.70 :    Leukemia

Title:  Phase I/II Trial of Bortezomib (Velcade®) in Combination with Mitoxantrone and Etoposide for Relapsed or Refractory Acute Leukemia

07C.162 :    Myeloma

Title:  Long-Term Observation Follow-up Study of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (240.../kg Plus Placebo to Mbilize and collect >6x10 CD34+ Cells/kg in Multiple Myeloma Patients for Autologus Transplantation (AMD3100-3102-LTF)

07C.163 :    Lymphoma

Title:  Long-Term Observational Follow-Up Study of a Multicenter, Randomized, Double-Blind, Placebo Controlled, Comparative Trial of AMD3100 (240...)Versus G-CSF (10../kg Plus Placebo to Mobilize and Collect >5x10 CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation (AMD3100-3101-LTF)

07C.303 :    Prostate

Title:  A Randomized Double-Blind Parallel Group Study Comparing Casodex 50 mg plus Placebo to Casodex 50mg plus dutasteride 3.5 mg Administered for 18 months to Men with Prostate Cancer Who have Failed First-Line Androgen Deprivation Therapy (Assessed by Rising PSA) Followed by a Two-Year Extension Phase

07C.348 :    Melanoma

Title:  A multicenter, randomized, double-blind study of dacarbazine with or without Genasense® in chemotherapy-naïve subjects with advanced melanoma and low LDH

07C.381 :    Brain & Central Nervous System

Title:  Phase I study of combination of Sorafenib and radiation therapy for the treatment of patients with brain metastases and primary brain tumors

07C.444 :    Hepatocellular

Title:  A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres) therapy for the treatment of Unresectable Hepatocellular Carcinoma

07C.446 :    Myelodysplastic Syndrome

Title:  A Phase I/II Dose-Finding Study of Lenalidomide in the Non-5q- LOW and INT-1 Risk MDS patientsand Mechanism of Cytopenia

07D.366 :    Hepatocellular

Title:  A humanitarian device exemption treatment protocol of Therasphere for treatment of unresectable hepatocellular carcinoma

07D.409 :    Gastric

Title:  Decision Counseling after Surgery for Patients with Periampullary Cancer

07F.149 :    Colorectal

Purpose:  A study to determine whether cetuximab plus chemotherapy, or cetuximab plus bevacizumab plus chemotherapy, is better than the combination of bevacizumab with chemotherapy for patients with cancer of colon or rectum.

Title:  CALGB #80405: A Phase III Trial of Irinotecan/ 5-FU/ Leucovorin with Bevacizumab, or Cetuximab (C225) or with the Combinations of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum.

07F.164 :    Breast

Title:  NSABP #B-42: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer

07F.248 :    Breast

Title:  SWOG #0500: (CIRB) A Randomized Phase III Trial to Test the Strategy of Changing Therapy Versus Maintaining Therapy for Metastatic Breast Cancer Patients who have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment (S0500) (NCI through ECOG)

07F.299R :    Prostate

Purpose:  To study how effective and safe prostate seed implants are for recurrent prostate cancer

Title:  A prospective Phase II trial of transperineal ultrasound-guided brachytherapy for locally recurrent prostate adenocarcinoma following external beam radiotherapy - RTOG 0526

07F.356 :    Lung & other Thoracic Malignancies

Title:  E1505: Phase III randomized trail of adjuvant chemotherapy with or without bevacizumab for patients with completely resected Stage 1B (> 4cm) –IIIA non small cell lung cancer (NSCLC)

07U.21 :    Lymphoma

Title:  A Pilot Trial of High Dose Intravenous Vitamin C in Patients with Refractory Non-Hodgkin Lymphoma

07U.68 :    Uveal Melanoma

Title:  An open-label uncontrolled single institution pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma

08C.131 :    Lymphoma

Title:  An Open Label, Randomized, Phase 2 Study of R-CHOP Plus Enzastaurin versus R-CHOP in the First-Line Treatment of Patients with Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

08C.191 :    Lung & other Thoracic Malignancies

Title:  A Randomized, Open-Labeled, Multinational Phase 3 Trial Comparing Amrubicin vs. Topotecan in Patients with Extensive or Limited and Sensitive or Refractory SCLC After Failure of First-line Chemotherapy.

08C.246 :    Melanoma

Purpose:  The primary objective of this study is to evaluate: -the efficacy of Marqibo as determined by Disease Control Rate (CR,PR or durable SD) in patients with metastatic uveal melanoma The secondary objectives of this study are to evaluate: -response rate (CR+PR) -progression free survival -overall survival -safety

Title:  A Phase 2 Study of Marqibo in Patients with Metastatic Uveal Melanoma

08C.301 :    Brain & Central Nervous System

Purpose:  A study to evaluate the safety of the drug ABT-888 when used with radiation therapy to treat cancer that has spread to the brain

Title:  A Phase I Study of Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination with Whole Brain Radiation Therapy in Subjects with Brain Metastases

08C.306 :    Colorectal

Purpose:  To demonstrate an improvement in progression-free survival (PFS) in patients with mCRC treated with sunitinib plus FOLFOX compared with bevacizumab plus FOLFOX in the first-line treatment setting

Title:  A Randomized, Phase 2 B Study of Sunitinib Plus Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) versus Bevacizumab plus FOLFOX as First-line treatment in patients with metastatic colorectal cancer

08C.447 :    Breast

Purpose:  The purpose of this study is to assess the potential value of SuperSonic Shear Wave Elastography for breast imaging. More specifically, this study aims to determine if this new Elastography mode can improve the characterization and the visualization of breast lesions.

Title:  Assessment of the Clinical Value of SuperSonic Shear Wave Elastography in the Ultrasonic Evaluation of Breast Lesions

08C.521 :    Colorectal

Purpose:  PRIMARY Part 1 (Phase 1b): To determine the maximum tolerated dose up to the target dose of 10 mg/kg Q2W of AMG 655 that can be administered in combination with mFOLFOX6/bevacizumab Part 2 (Phase 2): To estimate the efficacy, as determined by progression free survival, of AMG 655 (at two doses selected in part 1) in combination with mFOLFOX6/bevacizumab

Title:  A Phase 1b/2 Study of AMG 655 in Combination with Modified FOLFOX6 and Bevacizumab for the First-Line Treatment of Subjects with Metastatic Colorectal Cancer

08C.522 :    Brain & Central Nervous System

Purpose:  To determine the maximum tolerated dose (MTD) and a recommended phase II dose (RP2D) of vorinostat and radiotherapy in patients with brain metastases

Title:  Phase I Study of the Combination of Vorinosat and Radiation Therapy for the Treatment of Patients with Brain Metastases

08C.532 :    Myeloma

Purpose:  To define the objective response rate associated with the administration of vorinostat in combination with bortezomib to patients with relapsed and refractory multiple myeloma after at least 2 prior treatment regimens, who meet both of the following conditions: 1.) refractory to bortezomib, defined as no response or disease progression in 60 days 2.) relapsed, refractory, intolerant, and/or ineligible to other therapies, including an IMiD according to the investigator

Title:  An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

08D.182 :    Hepatocellular

Purpose:  Describe how patients with liver cancer and associated chronic pain differ from patients with liver cancer who do not experience chronic pain with respect to objective physical variables of tumor and liver descriptors (e.g., maximum tumor size, bilaterality, liver size, etc), mood and health related quality of life and to relate this to any significance for survival (OS). Describe the location, intensity and quality of pain description in patients with liver cancer who experience chronic pain and to relate this to tumor size, location and liver function.

Title:  Hepatic Cancer and Chronic Pain

08D.213 :    Pancreas

Purpose:  This is a Jefferson Pancreatic Tumor Registry that consists of patient, family and non-family questionnaires to be completed to collect and analyze data about family history, demographic variables and environmental/ occupational risk factors of current pancreatic cancer patients. They will also be utilizing DNA information from tissues already collected from the approved Tissue Banking protocol (06U.76). Blood samples will be collected from non Pancreatic Cancer patients.

Title:  Jefferson Pancreas Tumor Registry

08D.380 :    Pancreas

Purpose:  Determine if the addition of an intraoperative ethanol celiac plexus neurolysis (alcohol block) in patients undergoing surgical intervention for pancreatic cancer will result in a decrease in cancer associated pain.

Title:  A Randomized Controlled Trial of Intraoperative Celiac Plexus Neurolysis for Patients with Operable (Resectable and Unresectable) Pancreatic and Periampullary Cancer

08D.461 :    Lymphoma

Purpose:  Primary objectives To assess the safety and efficacy of combination immunotherapy with rituximab and interleukin-2 in patients with non-Hodgkin’s lymphoma Secondary objectives: Investigate overall survival

Title:  Phase II Study of IL-2 and Rituximab Maintenance in High Risk B Cell Non-Hodgkin’s Lymphoma

08D.85 :    Hematologic Malignancies

Title:  A Two Step Approach To Matched-Sibling Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematological Malignancies

08F.112 :    Ovary

Purpose:  To assess the ability of the YKL-40 serum marker to detect response or lack of response to primary chemotherapy in FIGO stage III or IV invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer. To compare the predictive accuracy of YKL-40 with CA125.

Title:  GOG #0235: A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Undergoing Primary Chemotherapy

08F.126 :    Breast

Purpose:  To determine the disease-free survival of patients (defined as invasive disease-free survival (IFDS) with lymph node positive and high risk lymph node negative breast cancer randomized to treatment with either doxorubicin/cyclophosphamide plus placebo followed by paclitaxel (AC + Placebo > T + Placebo) or the same chemotherapy regimen plus bevacizumab.

Title:  E5103: A Double Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

08F.173 :    Prostate

Title:  CALGB #90203: Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High Risk, Clinically Localized Prostate Cancer Protocol Activation Date: 12/15/06 including update #1

08F.263 :    Leukemia

Purpose:  • To determine if early treatment with chemoimmunotherapy comprising fludarabine phosphate and rituximab extends the time to second treatment in patients with genetically high-risk (unmutated IgVH), asymptomatic, previously untreated chronic lymphocytic leukemia (CLL). • To determine the time to disease progression that would warrant second treatment. • To determine overall survival.

Title:  CALGB #10501: A Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized To Early Intervention Versus Observation with Later Treatment in the High risk Genetic Subset with IGVh Unmutated Disease

08F.281 :    Renal

Purpose:  To determine the effect of the two different doses of AVE0005 (VEGF Trap) treatment on the progression-free proportion at 8 weeks in patients with metastatic renal cell carcinoma who had previous treatment with a tyrosine kinase inhibitor (TK1).

Title:  E4805-A Randomized Phase II Study to Determine the Effect of 2 Different Doses of AE0005 (VEGF Trap) in Patients with Metastatic Renal Cell Carcinoma

08F.291 :    Prostate

Purpose:  To formally assess the strategy of active surveillance (with treatment as needed) for low risk, early stage prostate cancer. The strategy will be compared to the strategy of treating patients with radiation or surgery.

Title:  PR.11: A Phase III Study of Active Surveillance Therapy Against Radical Treatment in Patients Diagnosed With Favorable Risk Prostate Cancer (START)(NCIC CTG PR.11/ECOG JPR.11)

08F.324 :    Prostate

Purpose:  Objectives: 1) To determine whether the addition of NC-STAD to PBRT improves freedom from progression (FFP) for 5 years, over that of PBRT alone in men treated with salvage RT after radical prostatectomy 2) To determine whether NC-STAD+PLNRT+PBRT improves FFP over that of NC-STAD+PBRT and PBRT alone in men treated with salvage RT after radical prostatectomy.

Title:  CIRB: RTOG 0534: A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy

08F.330 :    Lung & other Thoracic Malignancies, Breast, Prostate

Title:  RTOG#0517 Randomized Phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer Open to JKCCN only.

08F.34 :    Lung & other Thoracic Malignancies

Title:  RTOG 0617/NCCTG N0628/CALGB 30609/ECOG R0617: A Randomized Phase III comparison of Standard- Dose (60 Gy) Versus Highdose(74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer

08F.354 :    Prostate

Title:  RTOG 0622: A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3-D-CRT or IMRT Irradiation in High Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy

08F.382 :    Colorectal

Purpose:  An Evaluation of Preoperative Chemotherapy (capecitabine and oxaliplatin) and Radiotherapy using Intensity Modulated Radiation Therapy (IMRT) for Patients with Locally Advanced Rectal Cancer

Title:  RTOG 0822 - A Phase II Evaluation Of Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy (IMRT) In Combination With Capecitabine And Oxaliplatin For Patients With Locally Advanced Rectal Cancer

08F.387 :    Melanoma

Purpose:  To assess the response rate (confirmed and unconfirmed, complete and partial response) and 4-month progression-free survival rate of metastatic melanoma to BAY 43-9006 (sorafenib) plus CCI-779 (temsirolimus) or BAY 43-9006 (sorafenib) plus R115777(tipifarnib). To assess the safety and tolerability of therapy with these combinations, with anemphasis on long-term side effects and toxicities.

Title:  S0438: A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818)in Metastatic Melanoma

08F.414 :    Renal

Purpose:  To assess progression-free survival on each arm of combination targeted (CTT) compared to that of bevacizumab alone.

Title:  E2804: The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) with Bevacizumab, Sorafenib, and Tensirolimus in Advanced Renal Cell

08F.481 :    Breast

Purpose:  The main objective is to compare disease-free survival in patients receiving clodronate versus ibandronate versus zoledronic acid as adjuvant therapy for breast cancer.

Title:  S0307 – Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

08F.514 :    Esophageal

Purpose:  To evaluate if the addition of cetuximab to paclitaxel, cisplatin, and radiation improves overall survival compared to paclitaxel, cisplatin, and radiation alone in patients with esophageal cancer who are treated without surgery.

Title:  R0436 - A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery

08F.515 :    Head & Neck

Purpose:  To compare the overall survival of patients with recurrent or metastatic head and neck cancer treated with standard Cisplatin-based chemotherapy with or without Bevacizumab.

Title:  E1305 - A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

08F.588 :    Lung & other Thoracic Malignancies

Purpose:  To determine whether administering high dose thoracic radiotherapy, 70 Gy (2 Gy once-daily over 7 weeks) or 61.2 Gy (1.8 Gy once-daily for 16 days followed by 1.8 Gy twice-daily for 9 days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice-daily over 3 weeks) in patients with limited stage small cell lung cancer.

Title:  CALGB #30610/RTOG #0538: (CIRB) Phase III Comparison of Thoracic Radiotherapy regimens in patients with limited small cell lung cancer also receiving Cisplatin and Etoposide. CALGB 30610/RTOG 0538

08G.89 :    Colorectal

Purpose:  In order of priority, to determine (1) tailored navigation intervention (TNI) impact on colorectal cancer [CRC] screening utilization, (2) TNI impact on CRC screening preference, and (3) TNI impact on perceptions about CRC screening.

Title:  Increasing Colon Cancer Screening in Primary Care Among African Americans

08R.69 :    Brain & Central Nervous System

Title:  Surgical versus Nonoperative Treatment of Metastatic Epidural Spinal Cord Compression (MESCC). Quality of Life and Cost-Effectiveness Outcomes.

09C.05 :    Pancreas

Purpose:  Primary Objective: To demonstrate improvement in overall survival (OS) with aflibercept by comparison to placebo in patients treated with gemcitabine for metastatic pancreatic cancer.

Title:  A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer.

09F.132 :    Breast

Purpose:  To determine whether the addition of bevacizumab to the two designated regimens of chemotherapy plus trastuzumab improves invasive disease-free survival (IDFS) relative to the two designated regimens of chemotherapy plus Trastuzumab

Title:  NSABP BETH: A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

09F.20 :    Breast

Purpose:  To determine the value of trastuzumab given during radiation therapy (RT) compared to RT alone in preventing the subsequent occurrence of ipsilateral breast cancer recurrence, ipsilateral skin cancer recurrence, or ipsilateral ductal carcinoma insitu (DCIS) in women with HER2-positive DCIS resected by lumpectomy

Title:  NSABP #B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

09F.21 :    Lung & other Thoracic Malignancies

Title:  MARVEL: Marker Validation of Erlotinib in Lung Cancer A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlot

09F.44 :    

Purpose:  Phase II Component: To determine the feasibility of successfully delivering the ALTENS treatment (given with the Codetron unit). Phase III Component: To determine whether the ALTENS treatment reduces overall xerostomia burden, as measured by the University of Michigan 15-item Xerostomia-Related Quality of Life Scale compared to the pilocarpine treatment at 9 months from randomization.

Title:  RTOG0537: A Phase II/III Study Comparing Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia

94.9031R :    Prostate

Title:  A Longitudinal Study to Determine the Utility of Prostate Specific Antigen with Digital Rectal Examination as Tests for the Early Detection of Prostate Cancer

97.9197R :    Phase I Studies

Purpose:  A research study to test the overall safety of an experimental drug, CD4-802-2 and to determine the largest dose that can be given to humans safely when given to patients who have received a bone marrow transplantation using the marrow from an unrelateddonor.

Title:  Safety and Efficacy of a CD4 Peptide Analogue in GVHD Prophylaxis in Recipients of Unrelated Donor Bone Marrow Grafts

98.0614R :  Blood and surgical specimens  Colorectal

Title:  Guanylyl Cyclase C in Blood and Colorectal Cancer

TEST123 :    Bladder, Breast, Cervix

Purpose:  This is a test trial. Please ignore it.

Title:  Test Protocol -- Ignore. . . .

 :    Head & Neck

Title:  R0619: A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High Risk Postoperative Advanced Squamous Cell Carcinoma of the Head And Neck

 :    Colorectal

Purpose:  Primary objective: -To demonstrate improvement in overall survival (OS) with aflibercept by comparison to placebo in patients with colorectal cancer treated with FOLFIRI as second line treatment for metastatic disease. Secondary objectives: -To compare progression free survival (PFS) in the 2 treatment arms -To evaluate overall response rate (RR) in the 2 treatment arms -To evaluate the safety profile in the 2 treatment arms -To assess the pharmacokinetics of IV aflibercept -To assess immunogenicity of IV aflibercept

Title:  A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan / 5-FU Combination (FOLFIRI) after failure of an oxaliplatin based regimen (VELOUR)

107 records found.